Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Where this comes from
- Record sourced from PubMed, PMID 39666698.
- Also identified by DOI 10.1371/journal.pone.0315976 and PMC identifier 11637368.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0301271.].